{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:04:48Z","timestamp":1776974688640,"version":"3.51.4"},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA049639"],"award-info":[{"award-number":["P01 CA049639"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This study assessed the relevance of 2013 European LeukaemiaNet (<jats:styled-content style=\"fixed-case\">ELN<\/jats:styled-content>) response categories on patients treated with common frontline tyrosine kinase inhibitors (<jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>) in chronic myeloid leukaemia in chronic phase (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>). Four hundred and eighty\u2010seven patients treated with imatinib (400\u00a0mg; <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content> 400, <jats:italic>n<\/jats:italic>\u00a0=\u00a070; 800\u00a0mg; <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content>800, <jats:italic>n<\/jats:italic>\u00a0=\u00a0201), dasatinib (<jats:italic>n<\/jats:italic>\u00a0=\u00a0107) or nilotinib (<jats:italic>n<\/jats:italic>\u00a0=\u00a0109) were analysed. Intention to treat (<jats:styled-content style=\"fixed-case\">ITT<\/jats:styled-content>) analysis indicated that the proportion of patients falling into optimal, warning and failure <jats:styled-content style=\"fixed-case\">ELN<\/jats:styled-content> categories were 89%, 6%, 6% at 3\u00a0months, 78%, 17% and 6% at 6\u00a0months, and 75%, 13% and 13% at 12\u00a0months, respectively. Rates of optimal response at 3\u00a0months were 75% for <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content>400, 90% for <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content>800, 89% for dasatinib and 97% for nilotinib; 41%, 80%, 86% and 89% at 6\u00a0months; and 47%, 77%, 76% and 87% at 12\u00a0months, respectively. Patients achieving optimal response had longer eventfree (<jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>), failurefree (<jats:styled-content style=\"fixed-case\">FFS<\/jats:styled-content>), transformationfree (<jats:styled-content style=\"fixed-case\">TFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) compared to warning and failure responses at all\u2010time points. Treatment with imatinib 800, dasatinib or nilotinib predicted for achieving an optimal response. Optimal response predicted for significantly longer <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> FFS<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> TFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> at 3, 6 and 12\u00a0months, irrespective of the <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content> modality used. <jats:styled-content style=\"fixed-case\">ELN<\/jats:styled-content> response categories reliably predicted outcomes in <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients receiving commonly used <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>s.<\/jats:p>","DOI":"10.1111\/bjh.13936","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T08:22:14Z","timestamp":1454660534000},"page":"114-126","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Analysis of 2013 European LeukaemiaNet (<scp>ELN<\/scp>) responses in chronic phase <scp>CML<\/scp> across four frontline <scp>TKI<\/scp> modalities and impact on clinical outcomes"],"prefix":"10.1111","volume":"173","author":[{"given":"Preetesh","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"},{"name":"Department of Internal Medicine Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyothsna","family":"Dasarathula","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela","family":"Nogueras Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"},{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Dellasala","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24418"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403158"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462291"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-566323"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.440"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0025"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3869"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"e_1_2_8_14_1","first-page":"95","article-title":"Switching to nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML\u2010CP) with suboptimal cytogenetic response (CyR) on imatinib: first results of the LASOR trial","volume":"122","author":"Cortes J.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.12.002"},{"key":"e_1_2_8_16_1","first-page":"1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","volume":"114","author":"Deininger M.","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23864"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.153"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"e_1_2_8_22_1","first-page":"415","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes T.P.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091272"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1649-0"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154344"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348110"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26391"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490128"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00021-6"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3800"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1093-y"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.175"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-162388"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-407486"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402680"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012781"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090282"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23238"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166694"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04200.x"},{"key":"e_1_2_8_46_1","first-page":"451","article-title":"Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression \u2010 An update of the TIDEL\u2010II trial","volume":"118","author":"Yeung D.T.","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590315"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13936","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:26:33Z","timestamp":1696325193000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/bjh.13936"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13936","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]},"assertion":[{"value":"2015-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}